Clinical Trials
3 trialsNCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04716010 2023-08-18
Developing and Evaluating Product Messaging
University of North Carolina, Chapel Hill
Phase NA Completed
NCT03668418 2018-09-12
xenoZ
University of Pisa
Unknown